NCT Number: NCT04866329
Synthetic products used in industrial, pharmaceutical, agro-alimentary or agricultural fields are found in our environment. Thus, humans could be simultaneously exposed to several of these pollutants. Furthermore, these environmental agents exert or could exert adverse actions on fertility, by altering gamete and embryo quality through endocrine disruptor effects or through increase in oxidative stress in gonads (cellular pathway known to be involved in several human reproductive pathologies).
In this context, the objectives of the present project are to obtain descriptive and analytical data on woman and oocyte exposure to several environmental agents (bisphenols, ethynylestradiol and glyphosate). The relation between these pollutant measures in follicular fluid and urine (from women receiving follow-up of in vitro fertilization (IVF) protocol in the University hospital of Tours, France) and the oocyte quality, the IVF and pregnancy successes will be studied. Several oxidative stress biomarkers in blood and follicular fluid will be also measured for these women, who will complete a questionnaire on their lifestyles. Finally, thanks to in vitro approaches, the effects and the mechanisms of action (including oxidative stress) of these pollutants (alone or in cocktails) will be studied on granulosa cells from these patients.
Interested in participating?
Request Info18 year–43 year
Female
Observational
Tours, 37044, France
Location status: Recruiting
Claire VIGNAULT, MD
CONTACT
Claire VIGNAULT, MD
SUB_INVESTIGATOR
Fabrice GUERIF, MD-PhD
CONTACT
Fabrice GUERIF, MD-PhD
PRINCIPAL_INVESTIGATOR
After being informed about the project Fertenox during a meeting describing about the Fecondation In Vitro protocol, all women patients not opposing to participate in the study and to use individual information will be included in the research during the usual bacteriological exam performed 1-2 months before oocyte pick up in the University hospital. They will receive the questionnaire on their lifestyle during this exam.
On the eve of the oocyte pick up (at the end of ovarian stimulation) during the usual blood collection, three additional tubes of blood will be collected for each patient in the University hospital. Women will also receive the screw-top container for morning-after urine sample and the completion of the lifestyle questionnaire will be checked (some advices will be done if necessary to help patients to fill out the questionnaire). Samples will be treated, aliquoted and stored according to requirements the same day.
The day of the oocyte pick up, the first morning urine will be collected by patients at home (or otherwise in the hospital). The completed questionnaire will be recovered and follicular fluid and granulosa cells will be collected for each woman. Samples will be aliquoted and stored according to requirements the same day. Granulosa cells will be cultured for in vitro approaches in research labs the same day.
Tubes of blood, urine and follicular fluid will be coded and kept at -80°C in the University hospital until their shipment to laboratories, where analyses of pollutants (bisphenols, ethynylestradiol and glyphosate) and analyses of oxidative stress biomarkers (antioxidant vitamins, FRAP), activity of several enzymes (catalase, superoxide dismutase, glutathione peroxidase) and oxidized lipids) will be performed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Additional blood sampling at the end of ovarian stimulation monitoring (the eve of the oocyte pick-up)
Collection of the first urine in the morning on the day of the oocyte pick-up
Collection of follicular fluid and granulosa cells during oocyte pick-up.
Time frame: Baseline
Assessed by measure of ethinylestradiol in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: Baseline
Assessed by measure of ethinylestradiol in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: Baseline
Assessed by measure of bisphenols in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: Baseline
Assessed by measure of bisphenols in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Assessed by measure of glyphosate in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Assessed by measure of glyphosate in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Assessed by concentration of ethinylestradiol in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Assessed by concentration of ethinylestradiol in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Assessed by concentration of bisphenols in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Assessed by concentration of bisphenols in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Assessed by concentration of glyphosate in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Assessed by concentration of glyphosate in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Assessed by nuclear maturity of each collected punctured oocyte
Time frame: Day 2 and day 5/6 after oocyte pick up
Assessed by in vitro early embryo developmental competence of each punctured oocyte (Day 2 embryo morphology, ability to reach the blastocyst stage, Day 5/6 blastocyst morphology, blastocyst outcome (transfer, freezing, discarding)
Time frame: From day 7 after embryo transfer for beta hCG assay, at 8 weeks of amenorrhea for foetus cardiac activity and after birth
Assessed by confirmation of a clinical pregnancy (blood beta human chorionic gonadotropin assay: > 1000 Unity Intenational /L), by confirmation of on-going pregnancy (ultrasound measure of foetus cardiac activity) and by confirmation delivery of live and healthy birth
Time frame: baseline
Assessed by measure of antioxidant vitamins (carotenoids, vitamin E, retinol) by High Performance Liquid Chromatography
Time frame: Baseline
Assessed by measure of oxidized lipids (isoprostanoids) by LC-MS/MS
Time frame: Baseline
Assessed by measure of antioxidant power (FRAP: Ferric ion Reducing Antioxidant Power) by spectrophotometry
Time frame: Baseline
Assessed by measure of glutathione peroxidase activity by spectrophometry
Time frame: On the eve of baseline
Assessed by measure of plasma antioxidant vitamins (carotenoids, vitamin E, retinol) by HPLC
Time frame: On the eve of baseline
Assessed by measure of plasma oxidized lipids (isoprostanoids) by LC-MS/M
Time frame: On the eve of baseline
Assessed by measure of plasma antioxidant power (FRAP) by spectrophotometry
Time frame: On the eve of baseline
Assessed by measure of activities of glutathione peroxidase, catalase and superoxide dismutase in red blood cells by UV and visible spectrophometry
Time frame: baseline
Assessed by measure of oxidized lipids (isoprostanoids) by LC-MS/MS
Time frame: The 3 last months of lifestyles before baseline
Assessed by a questionnaire on sociodemographic characteristics, smoking, physical activity, professional and environmental expositions, consumption of dietary supplements (antioxidants), consumption of drinks (tap water, from plastic bottle, cans...), food reheating habit, consumption of food from tin box, use of hygiene and cosmetic products...
Time frame: after 24 or 48h of exposure
Assessed on cellular viability (CCK8, live-dead assay)
Time frame: after 24 or 48h of exposure
Assessed on proliferation (BrdU)
Time frame: after 48 or 72h of exposure
Assessed on steroid production (ELISA, LC-MS)
Time frame: after 1 or 24h of exposure
Assessed on energetic metabolism (mitochondrial and glycolytic activities by Seahorse and Omnilog assays)
Time frame: after 5, 6 or 24h of exposure
Assessed on oxidative stress biomarkers (reactive oxygen production, Nrf2 nuclear translocation by confocal microscopy, cytometry and fluorimetry)
Time frame: after 24, 48 or 72h of exposure
Assessed on protein expression (Western Blotting) of several markers of the studied functions (including oxidative stress)
Time frame: after 6 or 24h of exposure
Assessed on gene expression (RNAseq and Quantitative Reverse Transcription-PCR) of several markers of the studied functions (including oxidative stress)
Time frame: after 1, 5, 10, 30 and 60 min of exposure
Assessed on protein expression (Western Blotting ) of signaling pathways
Time frame: after 6h of exposure
Assessed on gene expression (RNAseq and qRT-PCR) of signaling pathways
Contact information is provided by the study sponsor or research team.
Fabrice GUERIF, MD-PhD
CONTACT
02.47.47.84.76 ext. +33
Virginie MAILLARD, PhD
CONTACT
02.47.42.79.71 ext. +33
University Hospital, Tours
Other
FERTilité féminine, Agents ENvironnementaux et Stress OXydant
Acronym: FERTENOX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07542600
Female Infertility, Female Urogenital Diseases
Františkovy Lázně, Carlsbad Region, Czechia
View Trial DetailsNCT03496636
Female Infertility, Female Urogenital Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT02741102
Female Infertility, Female Urogenital Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07546552
Bone Diseases, Bone Diseases, Metabolic
Skive, Midt Jylland, Denmark
View Trial Details